

 <p>(to be used for correspondence after initial filing)</p>	Application Number	09/979,539
	Filing Date	November 20, 2001
	First Named Inventor	Pastan, Ira H., et al.
	Art Unit	1642
	Examiner Name	Blanchard, David J.
Total Number of Pages in This Submission	Attorney Docket Number	015280-395100US


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement with PTO/SB/08 <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Cited References A8-A19; Return Postcard
<input type="checkbox"/> Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Laurence J. Hyman		
Date	August 31, 2005	Reg. No.	35,551

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Brenda J. Dolly	Date	Aug. 31, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



PATENT
Attorney Docket No.: 015280-395100US
Client Reference No.: E-139-1999/0-US-07

On Aug. 31, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Brenda J. Dolly
Brenda J. Dolly

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PASTAN et al.

Application No.: 09/979,539

Filed: November 20, 2001

For: IMMUNOCONJUGATES HAVING
HIGH BINDING AFFINITY

Examiner: Blanchard, David J.

Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

09/08/2005 HGUTEMA1 00000030 201430 09979539


01 FC:1806 180.00 DA

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.


Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Laurence J. Hyman
Reg. No. 35,551

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
LJH:ack



Substitute for form 1449A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/979,539
				Filing Date	November 20, 2001
				First Named Inventor	Pastan, Ira H.
				Art Unit	1642
				Examiner Name	Blanchard, David J.
Sheet	1	of	2	Attorney Docket Number	015280-395100US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-5,320,956	01-14-1994	Willingham et al.	
	A2	US-5,498,698	03-12-1996	Yamaguchi et al.	
	A3	US-5,723,318	03-03-1998	Yamaguchi et al.	
	A4	US-5,747,654	05-05-1998	Pastan et al.	
	A5	US-6,083,502	07-04-2000	Pastan et al.	
	A6	US-6,153,430	11-28-2000	Pastan et al.	
	A7	US-6,809,184 B1	10-26-2004	Pastan et al.	


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	A8	WO	92/07081	A2	04-30-1992	Gov. of USA, Dept. Health & Human Services		<input type="checkbox"/>
	A9	WO	97/25068	A2	07-17-1997	Gov. of USA, Dept. Health & Human Services		<input type="checkbox"/>
	A10	WO	97/34634	A1	09-25-1997	Sloan-Kettering Inst.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A11	BRINKMAN, U. et al., "Cloning and Expression of the Recombinant Fab Fragment of Monoclonal Antibody K1 that Reacts with Mesothelin Present on Mesotheliomas and Ovarian Cancers," <u>International Journal of Cancer</u> , May 16, 1997, Vol. 71, No. 4, pp. 638-644	
	A12	CHANG, K., et al., "Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers," <u>Proc. Natl. Acad. Sci. USA</u> , January 1996, Vol. 93, pp. 136-140.	
	A13	CHANG, K., et al., "Characterization of the Antigen (CAK1) Recognized by Monoclonal Antibody K1 Present on Ovarian Cancers and Normal Mesothelium," <u>Cancer Research</u> , Jan. 1, 1992, Vol. 52, No. 1, pp. 181-186.	
	A14	CHOWDHURY, P., et al. "Isolation of Anti-Mesothelin Antibodies From A Phage Display Library," <u>Molecular Immunology</u> , Jan. 1997, Vol. 34, No. 1, pp. 9-20	
	A15	CHOWDHURY, P., et al., "Improving antibody affinity by mimicking somatic hypermutation in vitro," <u>Nature Biotechnology</u> , June 1999, Vol. 17, pp. 568-572.	
	A16	COLMAN, P.M., "Effects of amino acid sequence changes on antibody-antigen interactions," <u>Research in Immunology</u> , 1994, Vol. 145, pp. 33-36.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form PTO/SB/08A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/979,539
				Filing Date	November 20, 2001
				First Named Inventor	Pastan, Ira H.
				Art Unit	1642
				Examiner Name	Blanchard, David J.
Sheet	2	of	2	Attorney Docket Number	015280-395100US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A17	DAVIES, J. et al., "Affinity improvement of single antibody VH domains: Residues in all three hypervariable regions affect antigen binding," <u>Immunotechnology</u> , 1996, Vol. 2, No. 3, pp. 169-179.	
	A18	DORNER, T., et al., "Delineation of Selective Influences Shaping the Mutated Expressed Human Ig Heavy Chain Repertoire," <u>J. Immunol.</u> , 1998, Vol. 160, No. 6, pp. 2831-2841.	
	A19	GREEN, N. et al., "Somatic hypermutation of antibody genes: a hot spot warms up," <u>BioEssays</u> , March 1998, Vol. 20, No. 3, pp. 227-234.	
	A20	HEIDELBERG, Database EMBL (EMPRO) EMBL, March 10, 1998	
	A21	KUBY, J., W.H., "Chapter 6: Antigen-Antibody Interactions," <u>Immunology, Second Edition</u> , Freeman and Company, New York, USA, 1994, pp. 136-134	
	A22	WU, G., et al., "Stepwise in vitro affinity maturation of Vitaxin, an $\alpha_v\beta_3$ -specific humanized mAb," <u>Proc. Natl. Acad. Sci. US</u> , May 1998, Vol. 95, pp. 6037-6042.	
	A23	YAMAGUCHI, N., et al., "A Novel Cytokine Exhibiting Megakaryocyte Potentiating Activity from a Human Pancreatic Tumor Cell Line HPC-Y5," <u>The Journal of Biological Chemistry</u> , 1994, pp. 805-808.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.